KVKoen van de Ven

Koen van de Ven

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Koen van de Ven has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Jørgen de Jonge

    Center for Infectious Disease Control National Institute for Public Health and the Environment Bilthoven The Netherlands

    9 shared publications
  • Harry van Dijken

    Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands

    8 shared publications
  • Stefanie Lenz

    National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands

    5 shared publications
  • Caroline Vilas Boas de Melo

    National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands

    3 shared publications
  • Debbie van Baarle

    Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands

    3 shared publications
  • Femke de Heij

    Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands

    3 shared publications

Latest Publications

  • Open Access

    Association between socioeconomic status and postoperative outcomes after esophagectomy within a universal healthcare system: a nationwide population-based cohort study

    by Lars van de Sanden, Teun J.L. Smits, Koen C.G.P. van de Ven, Grard A.P. Nieuwenhuijzen, Sjoerd M. Lagarde, Mark M.J. Nielen, Bas P.L. Wijnhoven, Misha D.P. Luyer, Suzanne S. Gisbertz, Richard van Hillegersberg, et al.

  • Open Access

    The Memory-CD8+-T-Cell Response to Conserved Influenza Virus Epitopes in Mice Is Not Influenced by Time Since Previous Infection

    by Josien Lanfermeijer, Koen van de Ven, Marion Hendriks, Harry van Dijken, Stefanie Lenz, Martijn Vos, José A. M. Borghans, Debbie van Baarle, Jørgen de Jonge

    To protect older adults against influenza A virus (IAV) infection, innovative strategies are imperative to overcome the decrease in protective immune response with age. One approach involves the boosting of CD8+ T cells at middle age that were previously induced by natural infection. At this stage, the immune system is still fit. Given the high conservation of T-cell epitopes within internal viral proteins, such a response may confer lasting protection against evolving influenza strains at older age, also reducing the high number of influenza immunizations currently required. However, at the time of vaccination, some individuals may have been more recently exposed to IAV than others, which could affect the T-cell response. We therefore investigated the fundamental principle of how the interval between the last infection and booster immunization during middle age influences the CD8+ T-cell response. To model this, female mice were infected at either 6 or 9 months of age and subsequently received a heterosubtypic infection booster at middle age (12 months). Before the booster infection, 6-month-primed mice displayed lower IAV-specific CD8+ T-cell responses in the spleen and lung than 9-month-primed mice. Both groups were better protected against the subsequent heterosubtypic booster infection compared to naïve mice. Notably, despite the different CD8+ T-cell levels between the 6-month- and 9-month-primed mice, we observed comparable responses after booster infection, based on IFNγ responses, and IAV-specific T-cell frequencies and repertoire diversity. Lung-derived CD8+ T cells of 6- and 9-month-primed mice expressed similar levels of tissue-resident memory-T-cell markers 30 days post booster infection. These data suggest that the IAV-specific CD8+ T-cell response after boosting is not influenced by the time post priming.


  • Open Access

    Modified influenza M158–66 peptide vaccination induces non-relevant T-cells and may enhance pathology after challenge

    by Josien Lanfermeijer, Koen van de Ven, Harry van Dijken, Marion Hendriks, Cami M. P. Talavera Ormeño, Femke de Heij, Paul Roholl, José A. M. Borghans, Debbie van Baarle, Jørgen de Jonge

    CD8 + T cells are promising targets for vaccination against influenza A virus (IAV) infection. Their induction via peptide vaccination is not trivial, because peptides are weakly immunogenic. One strategy to overcome this is by vaccination with chemically enhanced altered peptide ligands (CPLs), which have improved MHC-binding and immunogenicity. It remains unknown how peptide-modification affects the resulting immune response. We studied the effect of CPLs derived from the influenza M158–66 epitope (GILGFVFTL) on the T-cell response. In HLA-A2*0201 transgenic mice, CPL-vaccination led to higher T-cell frequencies, but only a small percentage of the induced T cells recognized the GILG-wildtype (WT) peptide. CPL-vaccination resulted in a lower richness of the GILG-WT-specific T-cell repertoire and no improved protection against IAV-infection compared to GILG-WT peptide-vaccination. One CPL even appeared to enhance pathology after IAV-challenge. CPL-vaccination thus induces T cells not targeting the original peptide, which may lead to potential unwanted side effects.


  • Open Access

    Influenza Infection in Ferrets with SARS-CoV-2 Infection History

    by Caroline Vilas Boas de Melo, Florence Peters, Harry van Dijken, Stefanie Lenz, Koen van de Ven, Lisa Wijsman, Angéla Gomersbach, Tanja Schouten, Puck B. van Kasteren, Judith van Den Brand, et al.

    During the COVID-19 pandemic, the use of face masks, social distancing, and isolation were effective not only in decreasing the circulation of SARS-CoV-2 but also in reducing other respiratory viruses, such as influenza. With fewer restrictions currently in place, influenza is slowly returning.


  • Open Access

    A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets

    by Koen van de Ven, Josien Lanfermeijer, Harry van Dijken, Hiromi Muramatsu, Caroline Vilas Boas de Melo, Stefanie Lenz, Florence Peters, Mitchell B. Beattie, Paulo J. C. Lin, José A. Ferreira, et al.

    Universal influenza vaccines should protect against continuously evolving and newly emerging influenza viruses. T cells may be an essential target of such vaccines, as they can clear infected cells through recognition of conserved influenza virus epitopes. We evaluated a novel T cell–inducing nucleoside-modified messenger RNA (mRNA) vaccine that encodes the conserved nucleoprotein, matrix protein 1, and polymerase basic protein 1 of an H1N1 influenza virus. To mimic the human situation, we applied the mRNA vaccine as a prime-boost regimen in naïve ferrets (mimicking young children) and as a booster in influenza-experienced ferrets (mimicking adults). The vaccine induced and boosted broadly reactive T cells in the circulation, bone marrow, and respiratory tract. Booster vaccination enhanced protection against heterosubtypic infection with a potential pandemic H7N9 influenza virus in influenza-experienced ferrets. Our findings show that mRNA vaccines encoding internal influenza virus proteins represent a promising strategy to induce broadly protective T cell immunity against influenza viruses.


  • Open Access

    PD-1 expression on mouse intratumoral NK cells and its effects on NK cell phenotype

    by Arnika K. Wagner, Nadir Kadri, Chris Tibbitt, Koen van de Ven, Sunitha Bagawath-Singh, Denys Oliinyk, Eric LeGresley, Nicole Campbell, Stephanie Trittel, Peggy Riese, et al.


  • Open Access

    A universal influenza mRNA vaccine candidate boosts T-cell responses and reduces zoonotic influenza virus disease in ferrets

    by Koen van de Ven, Josien Lanfermeijer, Harry van Dijken, Hiromi Muramatsu, Caroline Vilas Boas de Melo, Stefanie Lenz, Florence Peters, Mitchell B Beattie, Paulo J C Lin, José A. Ferreira, et al.

    Universal influenza vaccines have the potential to protect against continuously evolving and newly emerging influenza viruses. T cells may be an essential target of such vaccines as they can clear infected cells through recognition of conserved influenza virus epitopes. We evaluated a novel T cell-inducing nucleoside-modified mRNA vaccine that encodes the conserved nucleoprotein, matrix protein 1 and polymerase basic protein 1 of an H1N1 influenza virus. To mimic the human situation, we applied the mRNA vaccine as a prime-boost regimen in naïve ferrets (mimicking young children) and as a booster in influenza-experienced ferrets (mimicking adults). The vaccine induced and boosted broadly-reactive T cells in the circulation, bone marrow and respiratory tract. Booster vaccination enhanced protection against heterosubtypic infection with potential pandemic H7N9 influenza virus in influenza-experienced ferrets. Our findings show that mRNA vaccines encoding internal influenza virus proteins are a promising strategy to induce broadly-protective T-cell immunity against influenza viruses.


  • Open Access

    Varying Viral Replication and Disease Profiles of H2N2 Influenza in Ferrets Is Associated with Virus Isolate and Inoculation Route

    by Koen van de Ven, Harry van Dijken, Wenjuan Du, Femke de Heij, Justin Mouthaan, Sanne Spijkers, Sharon van Den Brink, Paul Roholl, Cornelis A. M. de Haan, Jørgen de Jonge

    In 1957 the world was subjected to a pandemic caused by an influenza A virus of the subtype H2N2. Although the virus disappeared in 1968, H2 viruses continue to circulate in avian reservoirs.


  • Open Access

    Influenza infection in ferrets with SARS-CoV-2 infection history

    by Caroline Vilas Boas de Melo, Florence Peters, Harry van Dijken, Stefanie Lenz, Koen van de Ven, Lisa Wijsman, Angéla Gommersbach, Tanja Schouten, Puck B. van Kasteren, van Den Brand Judith, et al.

    Non-pharmaceutical interventions (NPIs) to contain the SARS-CoV-2 pandemic drastically reduced human-to-human interactions, decreasing the circulation of other respiratory viruses as well. As a consequence, influenza virus circulation – normally responsible for 3-5 million hospitalizations per year globally – was significantly reduced. With downscaling the NPI countermeasures, there is a concern for increased influenza disease, particularly in individuals suffering from post-acute effects of SARS-CoV-2 infection. To investigate this possibility, we performed a sequential influenza H1N1 infection 4 weeks after an initial SARS-CoV-2 infection in the ferret model. Upon H1N1 infection, ferrets that were previously infected with SARS-CoV-2 showed an increased tendency to develop clinical symptoms compared to the control H1N1 infected animals. Histopathological analysis indicated only a slight increase for type II pneumocyte hyperplasia and bronchitis. The effects of the sequential infection thus appeared minor. However, ferrets were infected with B.1.351-SARS-CoV-2, the beta variant of concern, which replicated poorly in our model. The histopathology of the respiratory organs was mostly resolved 4 weeks after SARS-CoV-2 infection, with only reminiscent histopathological features in the upper respiratory tract. Nevertheless, SARS-CoV-2 specific cellular and humoral responses were observed, confirming an established infection. Thus, there may likely be a SARS-CoV-2 variant-dependent effect on the severity of disease upon a sequential influenza infection as we observed mild effects upon a mild infection. It, however, remains to be determined what the impact is of more virulent SARS-CoV-2 variants. Importance During the COVID-19 pandemic, the use of face masks, social distancing and isolation were not only effective in decreasing the circulation of SARS-CoV-2, but also in reducing other respiratory viruses such as influenza. With less restrictions, influenza is slowly returning. In the meantime, people still suffering from long-COVID, could be more vulnerable to an influenza virus infection and develop more severe influenza disease. This study provides directions to the effect of a previous SARS-CoV-2 exposure on influenza disease severity in the ferret model. This model is highly valuable to test sequential infections under controlled settings for translation to humans. We could not induce clear long-term COVID-19 effects as SARS-CoV-2 infection in ferrets was mild. However, we still observed a slight increase in influenza disease severity compared to ferrets that had not encountered SARS-CoV-2 before. It may therefore be advisable to include long-COVID patients as a risk group for influenza vaccination.

  • Open Access

    Pathology and immunity after SARS-CoV-2 infection in male ferrets is affected by age and inoculation route

    by Koen van de Ven, Harry van Dijken, Lisa Wijsman, Angéla Gomersbach, Tanja Schouten, Jolanda Kool, Stefanie Lenz, Paul Roholl, Adam Meijer, Puck van Kasteren, et al.

    Improving COVID-19 intervention strategies partly relies on animal models to study SARS-CoV-2 disease and immunity. In our pursuit to establish a model for severe COVID-19, we inoculated young and adult male ferrets intranasally or intratracheally with SARS-CoV-2. Intranasal inoculation established an infection in all ferrets, with viral dissemination into the brain and gut. Upon intratracheal inoculation only adult ferrets became infected. However, neither inoculation route induced observable COVID-19 symptoms. Despite this, a persistent inflammation in the nose was prominent in especially young ferrets and follicular hyperplasia in the bronchi developed 21 days post infection. These effects -if sustained- might resemble long-COVID. Respiratory and systemic cellular responses and antibody responses were induced only in animals with an established infection. We conclude that intranasally-infected ferrets resemble asymptomatic COVID-19 and possibly aspects of long-COVID. Combined with the increasing portfolio to measure adaptive immunity, ferrets are a relevant model for SARS-CoV-2 vaccine research.